Back to Search Start Over

Magnitude and relevance of change in health-related quality of life in patients with vascular malformations treated with sirolimus.

Authors :
Harbers, V.E.M.
Bouwman, F.C.M.
Rijnsoever, I.M.P. van
Verhoeven, B.H.
Vleuten, C.J.M. van der
Schultze Kool, L.J.
Laat, P.C.J. de
Horst, C.M. van der
Kievit, W.
Loo, D.M.W.M. te
Harbers, V.E.M.
Bouwman, F.C.M.
Rijnsoever, I.M.P. van
Verhoeven, B.H.
Vleuten, C.J.M. van der
Schultze Kool, L.J.
Laat, P.C.J. de
Horst, C.M. van der
Kievit, W.
Loo, D.M.W.M. te
Source :
Frontiers in Medicine; 2296-858X; 10; 1155476; ~Frontiers in Medicine~~~~~2296-858X~~10~~1155476
Publication Year :
2023

Abstract

Contains fulltext : 292754.pdf (Publisher’s version ) (Open Access)<br />INTRODUCTION: Vascular malformations are rare congenital anomalies of the vascular system, which can involve the capillaries, veins, arteries, lymphatics, or a combination of vessel types. Patients with vascular malformations experience an impaired health-related quality of life (HRQoL) because of their symptoms (e.g., pain, swelling, and bleeding) and psychosocial distress. Sirolimus is an effective drug used in the medical treatment of these patients; however, relatively little is known about the effect of sirolimus on specific changes in the HRQoL domains and its magnitude. METHODS: The magnitude of change (effect size) following intervention is more informative to clinical practitioners than statistically significant but clinically unimportant changes; therefore, this study aimed to examine the magnitude and meaningfulness of change in the HRQoL of children and adults with vascular malformations following sirolimus treatment using low target levels. RESULTS: In total, 50 patients with vascular malformations (19 children, 31 adults) were included in this study. These patients experienced a lower HRQoL than the general population, with the adults reporting a significantly lower score in almost all domains. A 6-month sirolimus treatment improved the HRQoL in 29 patients, including 77.8% of the children (Pediatric Quality of Life Inventory score [PedsQL]) and 57.7% of the adults (Short Form 36 [SF-36]). The effect sizes of sirolimus for each SF-36/PedsQL domain ranged from 0.19 to 1.02. The clinically relevant moderate magnitude of changes was seen in the domains of the children's reports: "Physical functioning" and "Social functioning" and in the domains of the parent reports: "Social functioning," "School functioning," and "Psychosocial." A high-magnitude change was seen in the domains "Emotional functioning" and "Psychosocial" in the children's reports and "Physical functioning" in the parent reports. In addition, the moderate magnitude of changes was also seen i

Details

Database :
OAIster
Journal :
Frontiers in Medicine; 2296-858X; 10; 1155476; ~Frontiers in Medicine~~~~~2296-858X~~10~~1155476
Publication Type :
Electronic Resource
Accession number :
edsoai.on1380687902
Document Type :
Electronic Resource